No Data
Merck, Eisai Update On Phase 3 LEAP-015 Trial; At Interim Analysis, Keytruda Plus Lenvima-based Regimen Showed Statistically Significant Improvement In Progression-free Survival
Weekly Buzz: Last Short Week of Jan Sees Records, Trump Gives Orders
Wall Street Today: Market Pulls Back After Wild Week
Unusual Options Activity: VFC, PDD and Others Attract Market Bets, VFC V/OI Ratio Reaches 315.8
Live Stock: First Week Down, Market Pulls Back a Hair After Records
Merck, Eisai Gastroesophageal Cancer Combo Therapy Meets One Primary Endpoint in Trial
Growth Investor27 : I own a lot & will buy more
DazzlerAus : agree but nothing seems to help
Youngman : I keep hearing nothing but good things about the stock while it goes down lol